Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients

Norway has one of the world’s highest incidences of colorectal cancer (CRC). Accumulating research suggests that the intestinal microbiota may have an important role in initiation and progression of colorectal cancer. In order to evaluate microbiome-based biomarkers for non-invasive detection of CRC...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 2019-07, Vol.38 (7), p.1367-1376
Main Authors: Tunsjø, Hege Smith, Gundersen, Gro, Rangnes, Fredrik, Noone, John Christopher, Endres, Alexander, Bemanian, Vahid
Format: Article
Language:English
Subjects:
Biomarkers
Biomedical and Life Sciences
Biomedicine
Biopsy
Cancer
Colon
Colorectal cancer
Colorectal carcinoma
E coli
Fusobacterium nucleatum
Genes
Internal Medicine
Intestinal microflora
Intestine
Medical Microbiology
Microbiomes
Microbiota
Mucosa
Original Article
Toxins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Norway has one of the world’s highest incidences of colorectal cancer (CRC). Accumulating research suggests that the intestinal microbiota may have an important role in initiation and progression of colorectal cancer. In order to evaluate microbiome-based biomarkers for non-invasive detection of CRC, the levels of Fusobacterium nucleatum and selected Escherichia coli toxin genes in stool and mucosa from a small cohort of Norwegian patients were investigated. The study cohort included 72 patients scheduled for colonoscopy. The patients were divided into three groups upon their examinations: cancer, polyp, and control groups. Levels of F. nucleatum in stool samples were significantly higher in the cancer group compared with the control group and the polyp group. High levels of F. nucleatum in stool reflected detection of F. nucleatum in the tumor tissues of colorectal cancer patients. However, no difference in the levels of E. coli toxin genes in neither stool nor biopsy samples between the patient groups was observed. This study suggests that a quantitative PCR assay targeting F. nucleatum in stool samples has the potential to be included in a larger panel of biomarkers for non-invasive testing for colorectal cancer.
ISSN:0934-9723
1435-4373
DOI:10.1007/s10096-019-03562-7